Sharing Bionanoplus experience
CEO Dr Hesham Salman
After three years of intensive efforts, 2010 was the year in which Bionanoplus was born in Navarra from the idea of the entrepreneur, Dr. Hesham Salman. Mr. Salman, PhD in Pharmacy from the University of Navarra, started to fulfill his dream as R&D director of Bionanoplus which is specialized in design of nanoparticles and microparticles as drug delivery systems. The full support of Navarra European Business Innovation Centre (CEIN) played a critical role in the successful transformation of the idea of Bionanoplus from dream to fact.
Technology and innovation
The main R&D strategy of Bionanoplus is focused on the development of bioadhesive polymeric nanoparticles and microparticles to enhance the effectiveness of biologically active molecules or chemical drugs in order to satisfy the need of clients in the pharmaceutical, personal care, veterinary and food markets. Bionanoplus aims to introduce the most important aspects of marketing at the moment of product development in the laboratory, and therefore, minimises the risks of technology transfers from lab to market. Thus, a simple technology based on an in situ self-assembled (SANP) polymeric nanoparticulate drug delivery system was designed by the Bionanoplus team in order to enhance the efficiency of therapeutic molecules.
The innovative products of Bionanoplus are based on new bioadhesive drug delivery systems which include novel and simple know-how in the area of manufacturing processes of polymeric nanoparticles for the encapsulation of active molecules. These systems have a high ability to adhere to the mucosa including oral, intestinal, ocular or skin surfaces. The bioadhesive capacity of Bionanoplus products enables the enhancement of the residence time of the therapeutic molecules in mucosal surfaces and thus increases their bioavailability.
Bionanoplus is collaborating with the Faculty of Pharmacy in the University of Navarra in the fields of nanoparticulate polymeric vectors and their potential applications in mucosal drug delivery strategies.
Facts & Figures
Bionanoplus raised a first round of funding of about 680.000 € from Inveready Seed Capital, Start Up Capital Navarra and Hesham Salman, which may raise to approximately 2 million € in 2013. The R&D team of Bionanoplus has a high capacity and competitive experience to design high quality products based on nanoparticulate drug delivery systems. Thus, Bionanoplus has developed innovative products based on bioadhesive and biocompatible nanosystems that can be applied for the local treatment of buccal and vaginal infections.
Pol. Mocholí. Plaza Cein 5, nave B14.
31110 Noáin. Navarra. Spain.